Publications on Clinical care from Johnson & Johnson
A filtered view. Show the full list.
Refine
Listings
-
Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study
Verified Author affiliations on the Europe PMC record name Drexel University College of Medicine, Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania, with Drexel University linked by the institution reference. Affiliation source
Clinical careAdded
-
Clinical trial reportArthritis & rheumatology (Hoboken, N.J.)
Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleBritish journal of clinical pharmacology
Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportClinical pharmacology in drug development
A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single-Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportClinical pharmacology in drug development
A Phase 1, Open-Label, Single-Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
A scalable workflow using digital cognitive assessment and pTau217 for MCI detection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportJournal of clinical pharmacology
Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleEJHaem
Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleJournal of pediatric gastroenterology and nutrition
Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleCPT: pharmacometrics & systems pharmacology
Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticlePulmonary circulation
Time to Therapy Activation and Initial Combination Therapy (TITANIC) for Patients With Pulmonary Arterial Hypertension
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticlePulmonary circulation
Use of Machine-Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportCancer immunology, immunotherapy : CII
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportCancer immunology, immunotherapy : CII
A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportCancer chemotherapy and pharmacology
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source
Clinical careAdded
-
Clinical trial reportJournal of neurology
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportJournal of neurology
Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleTargeted oncology
Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics
Verified Author affiliations on the Europe PMC record name Johnson & Johnson, Perelman School of Medicine, University of Pennsylvania. Affiliation source
Clinical careAdded
-
ReviewAdvances in therapy
Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAdvances in therapy
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAdvances in therapy
FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAdvances in therapy
Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAdvances in therapy
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ReviewAdvances in therapy
Golimumab for the Treatment of Axial Spondyloarthritis: Integrating Clinical Outcomes with Real-World Patient Benefits
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded